Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells $31,100.85 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 165 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $157.13, for a total transaction of $11,784.75.
• On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $152.80, for a total transaction of $11,460.00.

Becton, Dickinson and Company Stock Down 1.1%

Shares of NYSE:BDX traded down $2.10 during trading hours on Thursday, reaching $188.11. The stock had a trading volume of 1,353,617 shares, compared to its average volume of 2,623,575. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The firm’s 50 day moving average is $164.35 and its 200-day moving average is $160.49. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a market capitalization of $51.83 billion, a price-to-earnings ratio of 56.66, a P/E/G ratio of 13.38 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several large investors have recently modified their holdings of the company. Amundi increased its holdings in shares of Becton, Dickinson and Company by 11.4% in the 2nd quarter. Amundi now owns 1,816,703 shares of the medical instruments supplier’s stock valued at $274,922,000 after acquiring an additional 186,541 shares during the period. First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares during the last quarter. California State Teachers Retirement System increased its stake in Becton, Dickinson and Company by 14,668.6% in the second quarter. California State Teachers Retirement System now owns 69,907,953 shares of the medical instruments supplier’s stock valued at $10,579,171,000 after purchasing an additional 69,434,598 shares during the period. Studio Investment Management LLC increased its stake in Becton, Dickinson and Company by 11.2% in the second quarter. Studio Investment Management LLC now owns 11,872 shares of the medical instruments supplier’s stock valued at $1,797,000 after purchasing an additional 1,193 shares during the period. Finally, Wedmont Private Capital purchased a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $206,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BDX. The Goldman Sachs Group cut their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Jefferies Financial Group reissued a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Barclays upped their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $185.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.